MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- AMBALAL SARABHAI
AMBALAL SARABHAI Share Price (AMSA)
Here is the latest stock price and chart of AMBALAL SARABHAI. For more details, see the AMBALAL SARABHAI company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
Find Out: How to Profit from 21st Century's BIGGEST Revolution
| Live BSE Quotes | Oct 19, 2021 (Close) | ||
|---|---|---|---|
| Price (Rs)31.40 | Open (Rs) 32.00 | High (Rs) 32.65 | Low (Rs) 31.05 |
| % Change-0.95 | Volume 237,547 | Value (Rs) 7,525,393 | 52-Week H/L 65.00 / 16.60 |
| Live NSE Quotes |
|---|
| Not listed |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day -0.95% | 1 Month -3.53% | 3 Months -1.41% | 1 Year 63.97% | 5 Years (CAGR)* 32.39% | 10 Years (CAGR)* 19.65% |
* Compound Annual Growth Rate
| Valuation | ||||
|---|---|---|---|---|
| EPS (Rs)* 5.24 | P/E Ratio (x) 5.99 | Market Cap (Rs m) 2,406.29 | P/BV (x) 5.38 | Dividend Yield (%) 0.00 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
AMBALAL SARABHAI Share Price Today:
AMBALAL SARABHAI last traded price was down 1.0% to Rs 31.4 on the BSE. The total volume of shares traded was 0.2 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 1.4%. And the benchmark S&P BSE SENSEX was at 61,716.1 (down 0.1%).
Over the last 30 days, the AMBALAL SARABHAI share price is down 3.5%. And over the last one year, AMBALAL SARABHAI share price is up 64.0%.
The current market capitalisation of AMBALAL SARABHAI stands at Rs 2,406.29 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of September 2021, company promoters held 30.76% stake in AMBALAL SARABHAI, with no shares having been pledged. To know more, check out the latest shareholding pattern of AMBALAL SARABHAI.
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
- TRENDING ON EQUITYMASTER:
- Warren Buffett - The Value Investor
- Your Ultimate Guide to Penny Stock Investing
- How to Invest in Gold
- Basics of Value Investing
- Benjamin Graham
- The Best Bluechip Stocks to Buy
- How to Invest in Silver
- The Best Small-cap Stocks to Buy
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Best Stocks to Buy Today
- How to Use P/E for Successful Investing
- How to Find Undervalued Stocks
- Differences Between Trading and Investing
- SWOT Analysis for Stocks
- The Best Dividend Stocks to Buy
Today's Market
Sensex Snaps 7-Day Winning Streak, Nifty Falls Below 18,450; ITC Dips 6%(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
Related Views On News
Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)
Oct 8, 2021The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.
Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)
Sep 30, 2021The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.
5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)
Sep 3, 2021These companies are likely to benefit the most from Covid-19 vaccines.
Apollo Hospitals' Shares Rally Over 5%, Hit Record-High on Strong Results (Views On News)
Aug 16, 2021The company reported a 73% YoY increase in revenue driven by an uptick in the hospital and pharmacy business.
J B Chemicals & Pharma's Decent Performance Puts Stock in Focus (Views On News)
Aug 13, 2021The company seeks to expand the market for prescription lozenges with new launches this year.
More Views on NewsMost Popular
Is it Time to Switch from Tata Power to NTPC? (Profit Hunter)
Oct 11, 2021Given the huge run up in Tata Power, does it make sense to switch to NTPC?
This Proxy EV Stock Just got a Power Crisis Boost (Profit Hunter)
Oct 8, 2021After months of research, I've come across few stocks that excite me far more than the mainstream electric vehicle companies.
Rs 1 Lakh Invested in These Cryptos at the Start of 2021 Became Rs... (Views On News)
Oct 8, 2021These cryptos would have multiplied investors' wealth by as much as 10,000% in just nine months.
Top 5 'Digital India' Stocks (Views On News)
Oct 6, 2021These companies are leading the Government's US$1 tn 'Digital India' initiative.
5 Exciting 'Unlisted' Companies and How to Play Them (Views On News)
Oct 7, 2021Here's how you can invest in some of the most exciting start-ups of the decade.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2022
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: How to Profit from Sensex 100,000
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK AMBALAL SARABHAI
- Track your investment in AMBALAL SARABHAI with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AMBALAL SARABHAI
AMBALAL SARABHAI - TEVA PHARMA COMPARISON
COMPARE AMBALAL SARABHAI WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
FOLLOW
APP
EQUITYMASTER SUPPORTS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.